Prognostic predictors of immunotherapy in patients with small cell lung cancer

Abstract

Wang Yaqian, Du Yiwei, Wang Xing, Jia Junmei. Prognostic predictors of immunotherapy in patients with small cell lung cancer[J]. Journal of International Oncology, 2023, 50(3): 179-182.

References36

[1]	Wang S, Zimmermann S, Parikh K, et al. Current diagnosis and management of small-cell lung cancer[J]. Mayo Clin Proc, 2019, 94(8): 1599-1622. DOI: 10.1016/j.mayocp.2019.01.034. doi:S0025-6196(19)30126-0pmid:31378235
[2]	Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: from pathogenesis to treatment[J]. Semin Cancer Biol, 2022, 86(Pt 2): 595-606. DOI: 10.1016/j.semcancer.2022.03.006. doi:10.1016/j.semcancer.2022.03.006pmid:35276343
[3]	Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. DOI: 10.1038/s41572-020-00235-0. doi:10.1038/s41572-020-00235-0pmid:33446664
[4]	Vafaei S, Zekiy AO, Khanamir RA, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier[J]. Cancer Cell Int, 2022, 22(1): 2. DOI: 10.1186/s12935-021-02407-8. doi:10.1186/s12935-021-02407-8pmid:34980128
[5]	Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)[J]. J Thorac Oncol, 2018, 13(9): 1393-1399. DOI: 10.1016/j.jtho.2018.05.002. doi:10.1016/j.jtho.2018.05.002
[6]	Ricciuti B, Kravets S, Dahlberg SE, et al. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer[J]. J Immunother Cancer, 2019, 7(1): 87. DOI: 10.1186/s40425-019-0572-6. doi:10.1186/s40425-019-0572-6pmid:30922388
[7]	Keogh A, Finn S, Radonic T. Emerging biomarkers and the changing landscape of small cell lung cancer[J]. Cancers (Basel), 2022, 14(15): 3772. DOI: 10.3390/cancers14153772. doi:10.3390/cancers14153772
[8]	Benitez JC, Recondo G, Rassy E, et al. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors[J]. Q J Nucl Med Mol Imaging, 2020, 64(2): 162-174. DOI: 10.23736/S1824-4785.20.03250-1. doi:10.23736/S1824-4785.20.03250-1pmid:32107903
[9]	Lee YJ, Lee JB, Ha SJ, et al. Clinical perspectives to overcome acquired resistance to anti-programmed death-1 and anti-programmed death ligand-1 therapy in non-small cell lung cancer[J]. Mol Cells, 2021, 44(5): 363-373. DOI: 10.14348/molcells.2021.0044. doi:10.14348/molcells.2021.0044pmid:34001680
[10]	Sun C, Zhang L, Zhang W, et al. Expression of PD-1 and PD-L1 on tumor-infiltrating lymphocytes predicts prognosis in patients with small-cell lung cancer[J]. Onco Targets Ther, 2020, 13: 6475-6483. DOI: 10.2147/OTT.S252031. doi:10.2147/OTT.S252031
[11]	Acheampong E, Abed A, Morici M, et al. Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis[J]. Cells, 2020, 9(11): 2393. DOI: 10.3390/cells9112393. doi:10.3390/cells9112393
[12]	Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6): 619-630. DOI: 10.1200/JCO.20.01055. doi:10.1200/JCO.20.01055pmid:33439693
[13]	Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer[J]. Nat Rev Clin Oncol, 2020, 17(5): 300-312. DOI: 10.1038/s41571-019-0316-z. doi:10.1038/s41571-019-0316-zpmid:32055013
[14]	Tian Y, Zhai X, Han A, et al. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1): 67. DOI: 10.1186/s13045-019-0753-2. doi:10.1186/s13045-019-0753-2
[15]	Otoshi T, Nagano T, Tachihara M, et al. Possible biomarkers for cancer immunotherapy[J]. Cancers (Basel), 2019, 11(7): 935. DOI: 10.3390/cancers11070935. doi:10.3390/cancers11070935
[16]	Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors[J]. Cancer Discov, 2020, 10(12): 1808-1825. DOI: 10.1158/2159-8290.CD-20-0522. doi:10.1158/2159-8290.CD-20-0522pmid:33139244
[17]	Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer[J]. Cancer Cell, 2018, 33(5): 853-861. e4. DOI: 10.1016/j.ccell.2018.04.001. doi:S1535-6108(18)30172-7pmid:29731394
[18]	Kim ES, Velcheti V, Mekhail T, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial[J]. Nat Med, 2022, 28(5): 939-945. DOI: 10.1038/s41591-022-01754-x. doi:10.1038/s41591-022-01754-x
[19]	Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker[J]. Cancer Cell, 2021, 39(2): 154-173. DOI: 10.1016/j.ccell.2020.10.001. doi:10.1016/j.ccell.2020.10.001pmid:33125859
[20]	Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data[J]. Nat Rev Cancer, 2019, 19(5): 289-297. DOI: 10.1038/s41568-019-0133-9. doi:10.1038/s41568-019-0133-9pmid:30926931
[21]	Prisciandaro M, Antista M, Raimondi A, et al. Biomarker landscape in neuroendocrine tumors with high-grade features: current knowledge and future perspective[J]. Front Oncol, 2022, 12: 780716. DOI: 10.3389/fonc.2022.780716. doi:10.3389/fonc.2022.780716
[22]	Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities[J]. Cancer Cell, 2021, 39(3): 346-360. e7. DOI: 10.1016/j.ccell.2020.12.014. doi:10.1016/j.ccell.2020.12.014pmid:33482121
[23]	金莹, 陈亚梅, 胡晓, 等. 循环肿瘤DNA检测小细胞肺癌基因突变的可行性及其预后预测价值分析[J]. 中华医学杂志, 2020, 100(45): 3614-3621. DOI:10.3760/cma.j.cn112137-20200504-01412. doi:10.3760/cma.j.cn112137-20200504-01412
[24]	Roper N, Velez MJ, Chiappori A, et al. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer[J]. Nat Commun, 2021, 12(1): 3880. DOI: 10.1038/s41467-021-24164-y. doi:10.1038/s41467-021-24164-ypmid:34162872
[25]	Hu C, Dong J, Liu L, et al. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: a study of 247 cases from the National Cancer Center of China[J]. Thorac Cancer, 2022, 13(3): 338-345. DOI: 10.1111/1759-7714.14249. doi:10.1111/1759-7714.14249
[26]	Leonetti A, Facchinetti F, Minari R, et al. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges[J]. Cell Oncol (Dordr), 2019, 42(3): 261-273. DOI: 10.1007/s13402-019-00441-3. doi:10.1007/s13402-019-00441-3
[27]	Tanaka K, Isse K, Fujihira T, et al. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer[J]. Lung Cancer, 2018, 115: 116-120. DOI: 10.1016/j.lungcan.2017.11.018. doi:S0169-5002(17)30585-8pmid:29290251
[28]	Li W, Ye L, Huang Y, et al. Characteristics of notch signaling pathway and its correlation with immune microenvironment in SCLC[J]. Lung Cancer, 2022, 167: 25-33. DOI: 10.1016/j.lungcan.2022.03.019. doi:10.1016/j.lungcan.2022.03.019pmid:35381444
[29]	Dixon ML, Luo L, Ghosh S, et al. Remodeling of the tumor microenvironment via disrupting Blimp1⁺effector Treg activity augments response to anti-PD-1 blockade[J]. Mol Cancer, 2021, 20(1): 150. DOI: 10.1186/s12943-021-01450-3. doi:10.1186/s12943-021-01450-3
[30]	Bonanno L, Pavan A, Dieci MV, et al. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltra-ting lymphocytes[J]. Eur J Cancer, 2018, 101: 191-200. DOI: 10.1016/j.ejca.2018.06.023. doi:S0959-8049(18)30937-7pmid:30077124
[31]	Jiang M, Wu C, Zhang L, et al. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages Ⅰ-Ⅲ[J]. J Immunother Cancer, 2021, 9(5): e002339. DOI: 10.1136/jitc-2021-002339. doi:10.1136/jitc-2021-002339
[32]	Kanemura H, Hayashi H, Tomida S, et al. The tumor immune microenvironment and frameshift neoantigen load determine response to PD-L1 blockade in extensive-stage SCLC[J]. JTO Clin Res Rep, 2022, 3(8): 100373. DOI: 10.1016/j.jtocrr.2022.100373. doi:10.1016/j.jtocrr.2022.100373
[33]	Hardy-Werbin M, Rocha P, Arpi O, et al. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer[J]. Oncoimmunology, 2019, 8(6): e1593810. DOI: 10.1080/2162402X.2019.1593810. doi:10.1080/2162402X.2019.1593810
[34]	Li L, Pi C, Yan X, et al. Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors plus chemotherapy[J]. Front Oncol, 2021, 11: 697865. DOI: 10.3389/fonc.2021.697865. doi:10.3389/fonc.2021.697865
[35]	Qi WX, Xiang Y, Zhao S, et al. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab[J]. Cancer Immunol Immunother, 2021, 70(11): 3199-3206. DOI: 10.1007/s00262-021-02926-3. doi:10.1007/s00262-021-02926-3
[36]	Zhou K, Cao J, Lin H, et al. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 962173. DOI: 10.3389/fonc.2022.962173. doi:10.3389/fonc.2022.962173

Prognostic predictors of immunotherapy in patients with small cell lung cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References36

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[11]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.